Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

22.16 -0.24 (-1.07%)

Streaming Delayed Price Updated: 4:00 PM EST, Mar 6, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,324,043
Open	22.04
Bid (Size)	22.00 (100)
Ask (Size)	23.00 (100)
Prev. Close	22.40
Today's Range	21.63 - 22.31
52wk Range	13.40 - 28.35
Shares Outstanding	162,625,379
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors

March 03, 2026

From Acadia Pharmaceuticals Inc.

Via Business Wire

Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing ↗

March 03, 2026

PTC Therapeutics develops therapies for rare diseases, with a portfolio spanning commercial products and investigational candidates.

Via The Motley Fool

Performance

YTD	-15.7%	-15.7%
1 Month	-8.5%	-8.5%
3 Month	-19.2%	-19.2%
6 Month	-12.3%	-12.3%
1 Year	+25.8%	+25.8%

More News

Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome

March 02, 2026

From Acadia Pharmaceuticals Inc.

Via Business Wire

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Surpasses $1 Billion Revenue Milestone in 2025, Beats Q4 EPS Estimates ↗

February 25, 2026

Via Chartmill

ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) Emerges as a Value Stock with Strong Fundamentals ↗

February 06, 2026

Via Chartmill

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Growth Momentum and Technical Setup ↗

January 16, 2026

Via Chartmill

Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing ↗

March 02, 2026

Via The Motley Fool

Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing ↗

March 02, 2026

Via The Motley Fool

Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts ↗

February 27, 2026

Via Stocktwits

ACADIA (ACAD) Q4 2025 Earnings Call Transcript ↗

February 25, 2026

Via The Motley Fool

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview

February 25, 2026

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

February 23, 2026

From Acadia Pharmaceuticals Inc.

Via Business Wire

Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year ↗

February 23, 2026

Via The Motley Fool

This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50% ↗

February 23, 2026

Via The Motley Fool

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

February 04, 2026

From Acadia Pharmaceuticals Inc.

Via Business Wire

ACAD Stock Slumps 8% After Hours On Hurdle To EU Approval For Genetic Disorder Drug ↗

February 02, 2026

Via Stocktwits

Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union

February 02, 2026

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference

January 13, 2026

From Acadia Pharmaceuticals Inc.

Via Business Wire

Rhythm Pharmaceuticals Faces Gravity: FDA Delays and Valuation Pressures Cool 2025’s Biotech Darling

December 30, 2025

Via MarketMinute

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Growth Momentum and Technical Setup for Breakout ↗

December 25, 2025

Via Chartmill

Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026

December 18, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome

December 12, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound? ↗

December 03, 2025

Via The Motley Fool

Healthcare Investor Exits $13 Million Stake STAAR Surgical Stake as Alcon Deal Drama Looms ↗

December 03, 2025

Via The Motley Fool

PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million? ↗

December 03, 2025

Via The Motley Fool

Frequently Asked Questions

Is ACADIA Pharmaceuticals Inc. - Common Stock publicly traded?

Yes, ACADIA Pharmaceuticals Inc. - Common Stock is publicly traded.

What exchange does ACADIA Pharmaceuticals Inc. - Common Stock trade on?

ACADIA Pharmaceuticals Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for ACADIA Pharmaceuticals Inc. - Common Stock?

The ticker symbol for ACADIA Pharmaceuticals Inc. - Common Stock is ACAD on the Nasdaq Stock Market

What is the current price of ACADIA Pharmaceuticals Inc. - Common Stock?

The current price of ACADIA Pharmaceuticals Inc. - Common Stock is 22.16

When was ACADIA Pharmaceuticals Inc. - Common Stock last traded?

The last trade of ACADIA Pharmaceuticals Inc. - Common Stock was at 03/06/26 04:00 PM ET

What is the market capitalization of ACADIA Pharmaceuticals Inc. - Common Stock?

The market capitalization of ACADIA Pharmaceuticals Inc. - Common Stock is 3.60B

How many shares of ACADIA Pharmaceuticals Inc. - Common Stock are outstanding?

ACADIA Pharmaceuticals Inc. - Common Stock has 4B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.